Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Egrifta · Egrifta WR · Egrifta SV
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GHRH analogue
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Increases endogenous GH and IGF-1.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
The authorized goal is reduction of excess abdominal fat in that population. General-population weight-loss promotion and ipamorelin stacks are different claims with different evidence requirements.
Human evidence
Product-specific evidence supports reduction of excess abdominal fat in HIV-associated lipodystrophy, not general weight management.
Preclinical evidence
The clinical indication is narrower than proposed metabolic mechanisms.
Critical reading and limitations
Comparison of historical 2 mg regimens with WR and SV is not resolved by selecting the largest or smallest number. The guide ties each quantity to its formulation and keeps handbook claims separate from current labeling.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by EGRIFTA WR prescribing information, revised March 2025
1.28 mg · Amount per administration
- Frequency
- Once daily
- Duration
- According to indication follow-up; no general “cycle”.
- Route
- Subcutaneous
- Context
- US: adults with HIV and lipodystrophy; reduction of excess abdominal fat.
- Presentation
- Egrifta WR: 11.6 mg per vial.
- Interpretation
- WR formulation only. The whole vial is not one dose.
R13 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Egrifta SV current US label
1.4 mg · Amount per administration
- Frequency
- Once daily
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Same specific indication; different formulation.
- Presentation
- Egrifta SV: 2-mg-per-vial formulation.
- Interpretation
- WR and SV are not substitutable.
REG-EGR-SV · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
1–2 mg · Total daily amount
- Frequency
- Daily
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Handbook regimen; not a default for WR or SV.
- Presentation
- Page mixes references to historical formulations.
- Interpretation
- Dose depends on formulation. Do not substitute milligram for milligram.
manual01 · Page 144 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
US: approved product for adults with HIV lipodystrophy; not general weight loss. EU authorization not established in this packet.
Adverse effects and unknowns
Edema, arthralgia, glucose intolerance and hypersensitivity. Label contraindications: active malignancy, disrupted hypothalamic-pituitary axis, pregnancy and hypersensitivity. CYP-metabolized drugs and glucocorticoid replacement require interaction assessment.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Tesamorelin · 24 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06554717 · Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVRegistry status: RecruitingLast update posted: May 19, 2026Query verification: October 16, 2026
NCT03226821 · Body Composition and Adipose Tissue in HIVRegistry status: TerminatedLast update posted: May 19, 2026Query verification: October 16, 2026
Source issues and references
The official registry record NCT07481734 contains mock, fictional or example-study wording. It is excluded from ordinary trial listings pending source authentication. A registry entry does not establish that a genuine study was conducted or that clinical results exist. · NCT07481734
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- R13
- REG-EGR-SV
October 16, 2026
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026
- NCT07481734
ClinicalTrials.gov NCT07481734 — source-integrity review hold
October 18, 2026